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Transient elevations in Ca2+ have previously been shown to promote focal adhesion 
disassembly and cell motility. Yet the targets of these Ca2+ transients have not been fully 
examined. In this study, we demonstrate that CaMK-II, a Ca2+/calmodulin dependent 
protein kinase, is activated in response to β1 integrin engagement with fibronectin to 
influence fibroblast adhesion and motility. We also show that CaMK-II is dynamically 
localized to the cell surface using Total Internal Reflection Fluorescence microscopy 
  xii 
(TIRFm) and that inhibition of CaMK-II with two mechanistically distinct, membrane 
permeant inhibitors accelerates spreading on fibronectin, enlarges paxillin-containing focal 
adhesions and blocks cell motility. On the other hand, expression of constitutively active 
CaMK-II reduces cell attachment, eliminates paxillin from focal adhesions and decreases 
the phospho-tyrosine levels of both FAK and paxillin. Cell spreading, paxillin 
incorporation into focal adhesions and phospho-tyrosine levels of FAK and paxillin are 
restored when cells expressing constitutively active CaMK-II are subsequently treated with 
myr-AIP, a specific CaMK-II catalytic inhibitor. Like CaMK-II inhibition, constitutively 
active CaMK-II blocks cell motility. Thus, both CaMK-II inhibition and constitutive 
activation block cell motility through over-stabilization or destabilization of focal 
adhesions, respectively. These findings provide the first direct evidence that CaMK-II 
promotes focal adhesion turnover and thus enables cell motility by stimulating tyrosine 
dephosphorylation of focal adhesion proteins.   
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General Introduction 
 
 
 
Calcium/calmodulin-dependent protein kinase type II 
CaMK-II, a Ca2+/calmodulin-dependent kinase, is a ubiquitously expressed, multi-
purpose serine/threonine kinase that regulates numerous cellular functions ranging from 
cell cycle progression to neurite outgrowth in nascent axons (Easley et al. 2006; Faison et 
al. 2002; Fink et al. 2003; Lin et al. 2004; Morris et al. 1998; Rasmussen and Rasmussen 
1994; Rasmussen and Rasmussen 1995; Shen et al. 1998; Tombes et al. 1995). In all 
metazoans, CaMK-II is encoded by up to four genes (α, β, γ and δ), which can be 
alternatively spliced to form over three dozen different splice variants (Tombes et al. 
2003). In its native state, CaMK-II forms a dodecameric structure with each subunit 
possessing a relative mass (Mr) of 50-60 kDa. Each subunit consists of 4 major domains: 
catalytic, regulatory, variable and oligomerization domains (see appendix figure 1B) 
(Kolodziej et al. 2000; Tombes et al. 2003). Differences in CaMK-II splice variant 
localization and function are primarily attributed to alternative splicing sites within the 
variable domain (Tombes et al. 2003). The C-terminal oligomerization domain comprises 
the core of the dodecameric complex, with each N-terminal catalytic domain facing 
outward (see appendix figure 1A). This orientation upon assembly gives the native CaMK-
II protein complex the appearance of a bicycle wheel, with the oligomeric center serving as 
the core and the catalytic subunits resembling spokes.  
Upon signaling events that elevate cytosolic Ca2+ levels, Ca2+ binds to calmodulin. 
Activated calmodulin then binds to the regulatory domain on CaMK-II (sequence, 
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RRKLKGAILTTML) (Schulman et al. 1992). The conformational change that results from 
calmodulin binding relieves the tonic inhibition of the autoinhibitory domain (sequence, 
KKALRRQETVDAL) (Schulman et al. 1992). The autoinhibitory domain of one subunit 
is then exposed to the active site of the adjacent subunit in the dodecameric holoenzyme 
(Schulman et al. 1992). The autophosphorylation of the threonine (Thr) within the 
autoinhibitory domain (Thr286 in α, Thr287 in β, γ, and δ) confers Ca2+ independence and 
allows CaMK-II to regulate cellular processes well after the re-uptake of cytosolic Ca2+. 
While multiple CaMK-II isoforms exist and are involved in a variety of cellular 
functions, this study focuses on δc, the simplest cytosolic CaMK-II variant that is the major 
isoform expressed in NIH/3T3 cells. Recent work in our lab has shown the CaMK-II 
variants from different genes can compensate for one another suggesting that the catalytic 
domains in each gene product is functionally identical. Moreover, these catalytic 
similarities appear to be evolutionarily conserved as mouse δc CaMK-II can be used to 
rescue heart development in a β CaMK-II-depleted zebrafish embryo. 
 
 
 
β1 Integrin 
 
Integrin proteins have been implicated in a number of biological processes, which 
include embryogenesis, skin regeneration, muscle and cartilage formation, immune 
surveillance and cancer cell metastasis (Brakebusch and Fassler 2005). The integrin family 
of proteins are heterodimeric transmembrane receptors consisting of both an α and β 
subunit (Hynes 2002). Currently there are 18 known α’s and 8 β’s, which combine to form 
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24 different receptors (Hynes 2002). β1 represents the largest family of heterodimeric 
integrin receptors and are involved in 12 different ligand binding properties, all of which 
bind to components of the extracellular matrix (Brakebusch and Fassler 2005; Hynes 
2002). In neurons, α6β1 and α7β1 bind laminin to induce attachment (Brakebusch and 
Fassler 2005). In fibroblasts, the primary integrin heterodimer, α5β1, binds to fibronectin. 
Upon engagement with components of the extracellular matrix, integrin receptors 
associate with the actin cytoskeleton through the formation of protein complexes on the β1 
cytoplasmic tail known as focal adhesions. Focal adhesions are critical signaling and 
structural hubs found in migrating cells and are composed of dozens of proteins including 
talin, vinculin, focal adhesion kinase (FAK) and paxillin (Huttenlocher et al. 1995; 
Lauffenburger and Horwitz 1996; Ridley et al. 2003).  
 
 
Talin 
 
Talin is a 270 kDa anti-parallel homodimeric protein that is a major component of 
focal adhesions (Critchley 2004; Nayal et al. 2004). Talin contains a globular head domain 
that binds integrin, FAK, PIPKIγ, and actin. The tail domain of talin contains additional 
binding sites for integrin and actin and also vinculin (Critchley 2004; Ling et al. 2002). To 
initiate talin association with integrin, the FAK/src tyrosine kinase complex activates 
PIPKIγ and mediates its binding to talin. PIPKIγ then locally generates 
phosphatidylinositol (4,5) bisphosphate (PIP2) (Ling et al. 2002; Ling et al. 2003), which 
transiently associates with talin to increase its binding affinity for integrin (Critchley 2004; 
Ling et al. 2003). Talin association with integrin increases the receptor’s affinity for 
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components of the extracellular matrix, a process termed inside-out signaling (Critchley 
2004; Ling et al. 2003). 
 During cell motility, talin is highly regulated at the trailing edge of the cell, where 
focal adhesion breakdown is necessary. In the trailing edge of motile cells, talin is cleaved 
by the Ca2+-dependent protease, calpain II, into the globular head domain (80 kDa) and the 
rod-shaped tail domain (190 kDa) (Franco et al. 2004; Lee et al. 2004; Shao et al. 2006). 
This proteolytic cleavage event prevents talin from driving integrin-mediated re-
attachment to the extracellular matrix, a process that is essential to rapid focal adhesion 
assembly/disassembly at the leading edge of motile cells.  
 
 
Vinculin 
 
 Like talin, vinculin is conformationally activated by PIP2. Prior to activation, the C-
terminal tail of vinculin binds to the N-terminal head domain and occludes binding sites 
within the head domain (Bakolitsa et al. 2004; Critchley 2004). Activation of vinculin by 
PIP2 promotes its association with talin, α-actinin, Arp2/3, paxillin and actin (Bakolitsa et 
al. 2004; Chandrasekar et al. 2005; Critchley 2004; DeMali et al. 2002). Interestingly, 
vinculin is not required for focal adhesion formation as vinculin-null cells still form focal 
adhesions although these adhesions are smaller in size compared to wild-type cells 
(Critchley 2004). Rather than promote adhesion like talin, vinculin seems to stabilize focal 
adhesions by cross-linking talin and actin (see appendix figure 2). 
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Focal Adhesion Kinase 
 
 Focal adhesions kinase (FAK) is a tyrosine kinase that is activated in response to 
integrin engagement with the extracellular matrix. FAK plays a unique role in focal 
adhesion dynamics by serving as both a scaffolding protein for focal adhesion assembly 
and functions as a tyrosine kinase to induce focal adhesion turnover (Cox et al. 2006; Mitra 
et al. 2005; Mitra and Schlaepfer 2006). Structurally, FAK contains an N-terminal FERM 
(protein 4.1, ezrin, radixin and moesin) domain, a central catalytic domain, three proline-
rich domains and a C-terminal FAT (focal adhesion targeting) domain (Cox et al. 2006; 
Mitra et al. 2005; Mitra and Schlaepfer 2006). The FERM, proline-rich and FAT domains 
all are important in FAK association with integrin, paxillin, vinculin, talin and other 
proteins important in focal adhesion assembly and cell motility (Cox et al. 2006; Mitra et 
al. 2005; Mitra and Schlaepfer 2006).  
Upon integrin engagement, FAK dimerizes and autophosphorylates at Tyr397. This 
autophosphorylation event creates an SH2 binding domain that recruits src. Src then 
phosphorylates FAK on additional Tyr sites which include Tyr576/577 (promotes full 
activation of FAK), Tyr861 (SH3 domain for p130CAS association) and Tyr925 (SH2 
domain for paxillin, talin and p190RhoGEF) (Mitra et al. 2005). FAK also recruits and 
activates PLCγ, PI3-K and p120RasGAP (Mitra et al. 2005; Mitra and Schlaepfer 2006), 
implicating FAK in multiple signaling pathways. Tyrosine phosphatases SHP-2 and SOCS 
deactivate FAK signaling and promote focal adhesion turnover (Cox et al. 2006; Mitra and 
Schlaepfer 2006). FAK also appears to be important in focal adhesion dynamics and cell 
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motility in that FAK-null fibroblasts form focal adhesions containing talin and vinculin, 
but these cells fail to migrate (Ilic et al. 1995).  
 
 
Paxillin 
 
Paxillin is 68 kDa scaffolding protein that contains numerous binding sites for 
incorporation into focal adhesions. Paxillin contains an integrin-association domain, SH2 
and SH3 domains, and LIM domains which are all necessary for association with integrin, 
FAK, vinculin, talin and a variety of other focal adhesion proteins (Schaller 2001; Turner 
2000). Paxillin is phosphorylated by the FAK/src complex on Tyr31 and Tyr118 to form a 
SH3 domain critical for Crk association (an event important in focal adhesion assembly) 
(Bellis et al. 1995; Schaller and Parsons 1995; Webb et al. 2005). Regulation of paxillin by 
Ser/Thr phosphorylation is not well understood, although Ser/Thr phosphorylation does 
occur prior to mitosis and upon integrin engagement with the extracellular matrix (Schaller 
2001; Turner 2000; Webb et al. 2005). Like FAK, paxillin seems to be essential for focal 
adhesion dynamics as paxillin-null fibroblasts exhibit strong defects in cell motility and 
focal adhesion turnover (Hagel et al. 2002; Webb et al. 2004).  
 
 
SHP-2 
 
The SH2-domain-containing tyrosine phosphatase, SHP-2 (also known as PTP1D 
and PTPN11), is a non-receptor phosphatase involved in both cell migration and ERK 
signaling (Poole and Jones 2005). During cell migration, SHP-2  translocates from the ER 
to focal adhesions in response to src signaling (Wang et al. 2006) to dephosphorylate FAK 
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on Y925 and paxillin on Y31, thus promoting focal adhesion turnover and detachment from 
the extracellular matrix (Vadlamudi et al. 2002). Furthermore, inhibition of SHP-2, 
expression of dominant-negative SHP-2 or SHP-2 knockout increase focal adhesion size 
and block cell motility (Inagaki et al. 2000; MacGillivray et al. 2003; Manes et al. 1999; 
Wang et al. 2005; Yu et al. 1998). These results suggest that SHP-2 is essential for focal 
adhesion dynamics in motile cells. 
 SHP-2 is activated by either src signaling (Tyr453) or Gab1, in which binding 
induces a conformational change and a subsequent elevation in phosphatase activity 
(Cunnick et al. 2001; Poole and Jones 2005). Studies detailing Ser/Thr regulation of SHP-2 
are limited but suggest that Ser/Thr phosphorylation may play a role in modulating 
tyrosine phosphatase activity.   
 
 
Gab1 
 
 The Grb2 associated binder 1 (Gab1) protein is a 110 kDa adapter protein that has 
been best characterized by its ability to bind Grb2 to modulate Ras activation (Holgado-
Madruga et al. 1996; Ingham et al. 2001; Takahashi-Tezuka et al. 1998; Weidner et al. 
1996). Gab1 also is recruited to the plasma membrane in response to receptor tyrosine 
kinase (RTK) signaling where it is phosphorylated on numerous Tyr residues to form SH2 
and SH3 binding domains (Cunnick et al. 2001; Gual et al. 2000; Lehr et al. 1999; Rocchi 
et al. 1998). In particular, Gab1 binds to and activates PLCγ, PI3-K and SHP-2 by inducing 
conformational changes in each enzyme (Gual et al. 2000). More recently, Gab1 has been 
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shown to mediate vascular endothelial cell migration and capillary tube formation through 
PI3-K and SHP-2 signaling (Rocchi et al. 1998; Yu et al. 2001).   
 
 
c-Abl 
 
 Like CaMK-II, c-abl is a ubiquitously expressed, highly conserved kinase that is 
involved in numerous cellular functions such as cell proliferation, differentiation and cell 
adhesion (Hernandez et al. 2004; Plattner et al. 2003; Plattner and Pendergast 2003). c-abl, 
also known as Abl1, is localized to both the nucleus and cytosol. Within the nucleus, c-abl 
is maintained in an inactive state through direct interaction with Rb (retinoblastoma) 
(Hernandez et al. 2004). Upon Rb hyperphosphorylation, c-abl is activated and promotes 
S-phase progression by phosphorylating Tyr residues on the C-terminus of RNA 
Polymerase II (Hernandez et al. 2004; Plattner et al. 2003). In the cytosol, c-abl remains 
inactive through its interaction with PIP2. Upon signaling events (including integrin 
engagement with FN), PIP2 is catalyzed and c-abl is activated by the src-family kinases 
(Plattner et al. 2003; Plattner and Pendergast 2003). c-abl can also be phosphorylated on 
Ser/Thr residues within its 14.3.3 protein binding domain which may influence both 
localization and activation.  
 c-abl influences cell motility by phosphorylating both paxillin and Crk to promote 
attachment to extracellular matrix through integrin receptors (Plattner et al. 2003). 
Likewise, c-abl is involved in actin cytoskeleton rearrangements through both direct 
interaction with F-actin and activation of small GTPases, Rho and Rac (Plattner et al. 
2003).   
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Rationale 
 
Cell motility is a complex cellular process that is essential throughout embryonic 
development, cancer cell metastasis, and immune surveillance. An important component to 
cell motility is the cyclical formation and breakdown of focal adhesions (known as focal 
adhesion turnover). Focal adhesion formation involves the attachment of integrins to 
components of the extracellular matrix and the subsequent recruitment of focal adhesion-
associated proteins such as FAK (focal adhesion kinase), paxillin, vinculin, talin, et al. 
While many studies have focused on the formation of focal adhesions in motile cells, much 
less is understood regarding the requisite breakdown of focal adhesions. 
Previous studies have implicated CaMK-II in cell motility in various cell types. For 
example, in Chinese hamster ovary (CHO) cells, a mutation of Thr38 to Ala38 on ICAP-1α 
(integrin cytosolic domain associated protein 1 α) prevents CaMK-II phosphorylation and 
initiates cell spreading in a similar fashion to CaMK-II inhibition. In human mammary 
epithelial (HME) cells, CaMK-II has been shown to phosphorylate β1 integrin on Thr788 
and Thr789. While both of these studies have clearly suggested a role for CaMK-II 
phosphorylation in motility, neither study clearly defines the notion that CaMK-II activity 
promotes disassembly and detachment. In this study, we show that CaMK-II promotes 
focal adhesion disassembly by inducing tyrosine dephosphorylation of FAK and paxillin, 
thus enabling cell motility. 
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CHAPTER 1: Integrin Engagement with the Extracellular 
Matrix Activates CaMK-II 
 
Integrins mediate cell adhesion by linking components of the extracellular matrix 
with the internal cytoskeleton but also initiate signals for a variety of other cellular 
functions (Brakebusch and Fassler 2005). Integrins are heterodimeric transmembrane 
receptors that consist of both an α and β subunit, of which 24 different combinations are 
known (Hynes 2002). In embryonic fibroblasts, the primary integrin heterodimer is α5β1, 
which binds to fibronectin (FN) (Brakebusch and Fassler 2005; Hynes 2002). Previous 
studies have shown that integrin engagement with FN induces localized Ca2+ transients that 
are critical for both focal adhesion turnover and cell motility (Conklin et al. 2005; Franco 
et al. 2004; Giannone et al. 2004; Giannone et al. 2002; Lee et al. 2005; Marks and 
Maxfield 1990; Shao et al. 2006).    
 In differentiating P19 neurons, the principal integrin complex is α6β1, which binds 
laminin-1 (EHS laminin) (Brakebusch and Fassler 2005). Laminin is an extracellular 
matrix protein that influences preneuronal cell migration and epithelial morphogenesis and 
promotes neurite outgrowth and axonal specification (Ekblom et al. 2003; Miner and 
Yurchenco 2004). Similar to FN, integrin engagement with laminin increases cytosolic 
Ca2+ levels, an event that can cause profound effects on developing neurons. Specifically, 
transient elevations in Ca2+ influence gene expression, neurite morphogenesis, and axon 
guidance (Bolsover 2005; Easley et al. 2006; Henley and Poo 2004; Henley et al. 2004). 
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 While integrin receptor activation has been shown in several cell types to induce 
localized Ca2+ transients, the targets of these transients have not been fully examined. In 
both neurons and fibroblast cells, CaMK-II, a Ca2+/calmodulin dependent kinase, has been 
implicated as a potential target of integrin-mediated Ca2+ release and has been shown to be 
important in cell motility and neurite outgrowth (Blystone et al. 1999; Easley et al. 2006; 
Illario et al. 2005). However, elevations in CaMK-II activity have not been specifically 
evaluated in response to integrin engagement with components of the extracellular matrix. 
In this study, we show that CaMK-II is activated by integrin receptor engagement with 
either FN or laminin in two different cell lines, NIH/3T3 fibroblasts and P19 neurons.    
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Materials and Methods 
 
NIH/3T3 culture- NIH/3T3 cells were cultured on tissue culture dishes (Nunc, Rochester 
NY) at 37˚C in DMEM with 10% fetal bovine serum (FBS; Invitrogen, Carlsbad CA). 
Cells were sub-cultured every 3 to 4 days, never exceeding 95% confluency. When 
specified, dishes were pre-incubated with 1 µg/ml human fibronectin (Invitrogen) in PBS 
(Phosphate Buffered Saline) for 1 hour at 37˚C or overnight at 4˚C, washed once with PBS 
and then placed into DMEM/10% FBS just prior to plating cells. 
 
P19 embryonal carcinoma cell culture- The P19 mouse diploid cell line was derived from 
an embryonic day 7 (E7) embryo and can be induced to differentiate by retinoic acid via 
embryoid body formation (McBurney et al. 1982). Undifferentiated P19 cells were 
maintained in DMEM (Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum 
(FBS). For the induction of differentiation, cells were cultured at 1 × 105 cells/ml in 
DMEM, 5% FBS, 5 × 10−7 M all trans-retinoic acid (ATRA) in bacteriological Petri dishes 
for 4 days (Yao et al. 1995). Induction yields embryoid bodies, which were then plated at 
2–5 × 105 cells/cm2 on culture dishes. Dishes were precoated with EHS laminin 
(Invitrogen) in neurobasal medium containing N2 supplement (Invitrogen). Poly-L-lysine 
(Sigma Chemical, St. Louis, MO) pretreatment was at 0.01% for 1 hour in dH2O. The only 
culture modification was that cytosine arabinoside, which suppresses the growth of 
undifferentiated cells, was not added after plating (Yao et al. 1995).  
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Whole cell lysate preparation- Cells were harvested with trypsin–EDTA and then washed 
with ice-cold PBS. Pellets were immediately resuspended in ice-cold homogenization 
buffer, which consisted of 30 mM HEPES, pH 7.4, 2.6 mM EGTA, 20 mM MgCl2, 80 mM 
β-glycerol phosphate, 0.1 µM okadaic acid (Life Technologies), 0.01 mg/ml each 
chymostatin, leupeptin, aprotinin, pepstatin, and soybean trypsin inhibitor (Sigma). 
Samples were then sonicated (two 5-second bursts on ice), centrifuged at 10,000×g for 15 
minutes at 4°C. This buffer was previously optimized for maximal CaMK-II recovery 
(Tombes et al. 1995; Tombes et al. 1999). Protein concentrations were determined using 
the BCA assay (PIERCE, Rockford, IL). 
 
CaMK-II activity assay- Total CaMK-II activity was assessed by measuring phosphate 
incorporation into a peptide substrate. Reactions were carried out in a total volume of 25 µl 
containing final concentrations of 20 mM HEPES (pH 7.4), 0.1 mM dithiothreitol, 15 mM 
magnesium acetate, 20mM β-glycerophosphate, 0.5 µM PKA inhibitor peptide, 0.1 µM 
okadaic acid, 40 µM sodium orthovanadate, 0.5 mCi [γ-32P-ATP], 35 µM autocamtide-2 
(peptide substrate), 1 µM calmodulin, 1 mM EGTA, and 3 mM Ca2+. After 10 minutes at 
30°C, 20 µl was pipetted onto P81 phosphocellulose paper squares that were air dried for 1 
minute and washed five times in 500 ml 1% phosphoric acid. Dried paper squares were 
quantitated by Cerenkhov counting. The sequence of autocamtide-2 is 
KKALRRQETVDAL. These assay conditions were optimized for compatibility with the 
buffer in which cell lysates were prepared (Tombes et al. 1995; Tombes et al. 1999). % 
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CaMK-II activation is determined as the percentage of total CaMK-II activity tha is Ca2+ 
independent.  
 
Immunolocalization- Cells were fixed in methanol at −20°C for 5 minutes for integrin 
staining. All other samples were fixed in 4% formaldehyde, phosphate-buffered saline 
(PBS), at 4°C for 15 minutes. Formaldehyde-fixed cells were then permeabilized for 5 
minutes in 0.1% NP40, PBS. All fixed cells were blocked for 30 minutes in Tris-buffered 
saline, pH 7.4, with 0.1% Tween 20 (TBST), containing 5% bovine serum albumin and 2% 
appropriate preimmune serum. Cells were then incubated in primary antibody at 2–5 µg/ml 
for 2 hours in 2% BSA, TBST, washed three times in TBST, incubated in secondary 
antibody at 2 µg/ml in blocking solution for 1 hour, washed three times in TBST, and 
imaged or stored in PBS at 4°C until ready for imaging. 
 
Reagents- The CaMK-II phosphor-Thr287 antibody was from Upstate Biotechnology Inc 
(Lake Placid, NY). The β1 integrin blocking antibody was from BD Biosciences (San Jose, 
CA). All secondary antibodies were obtained from Jackson ImmunoResearch Laboratories 
(West Grove, PA). The RGD peptide (GRGDNP) is a competitive inhibitor of fibronectin 
binding to the β1 subunit of integrin and was obtained from GenScript Corp (Scotch Plains 
NJ). An alternative non-competing peptide (GRADSP) was obtained from Calbiochem. 
These peptides were incubated with cells just prior to plating at final peptide 
concentrations of 1 mM. KN-93, a reversible calmodulin antagonist of CaMK-I, CaMK-II, 
and CaMK-IV, and KN-92, an inactive analog (Sumi et al. 1991) were obtained from 
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CalBiochem(La Jolla, CA). The sequence of the myristoylated auto-inhibitory peptide 
(myr-AIP) was KKALRRQEAVDAL (BioMol, Plymouth Meeting PA). The stock 
concentration of these compounds was 5mM in dH2O.  
 
Statistical Analyses- For CaMK-II activity assays, the average value +/- standard error are 
shown from samples performed in triplicate. Data are representative of multiple 
experiments. Statistical significance was determined with Student’s t-tests with p < 0.05.  
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Results 
 
β1 integrin engagement with fibronectin activates CaMK-II in NIH/3T3 cells. FN 
binding to β1 integrin has been shown to induce localized transient Ca2+ elevations 
(Praetorius et al. 2004). To determine whether CaMK-II is a target of these Ca2+ transients, 
the degree of CaMK-II activation was measured in NIH/3T3 cells 3 hours after sub-
culturing on dishes pre-coated with 1 µg/ml FN. To avoid the influence of other adhesion 
molecules such as vitronectin, cells were cultured in serum-free medium. Fibroblasts sub-
cultured on 1 µg/ml laminin did not spread (Fig 1A) and exhibited a significant reduction 
(p < 0.01) in CaMK-II activation as compared to cells cultured on FN (Fig. 1B). Pre-
incubation with either an anti-β1 integrin blocking antibody or a peptide containing 
Arginine-Glycine-Aspartate (RGD) decreased cell spreading on FN and significantly 
reduced (p < 0.01) CaMK-II activation as compared to incubation with a control IgG or a 
control peptide (RAD).   
 
β1 blockade prevents natural CaMK-II activation in P19 neurons. Integrin 
activation by laminin in neurons has also been shown to induce localized Ca2+ transients 
(Bixby et al. 1994; Gomez et al. 2001; Kuhn et al. 1998). To demonstrate that CaMK-II is 
activated in response to integrin engagement with laminin, neurons were grown on laminin 
for 22 hours, treated for 2 hours with the indicated CaMK-II inhibitor or integrin blocking 
antibody (CD29), harvested and quantified for CaMK-II activity. Although assays of cell 
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lysates are reflective of the entire culture (neuronal and non-neuronal cells), activated 
CaMK-II is predominantly neuronal. CaMK-II activation in untreated P19 neurons was 
higher (7.3%) than in uninduced P19 embryonal carcinoma cells (3.2%), a result consistent 
with the natural activation of CaMK-II during neuronal induction (Figure 2). Likewise, 
disruption of β1 integrin engagement with laminin reduced CaMK-II activity similar to 
treatment with CaMK-II inhibition (Figure 2). 
 Because both protein expression and basal levels of CaMK-II activity increase 
upon neural induction (Johnson et al. 2000), P19 neurons can be stained with a phospho-
specific CaMK-II antibody directed at the autophosphorylation site, Thr287. To 
complement CaMK-II activity data, P19 neurons were cultured on laminin for 22 hours 
and then left untreated or treated with CaMK-II inhibitors (as indicated) or CD29 for 2 
hours (Figure 3). Neurons were then fixed and stained for phospho-Thr287. Neurons treated 
with either CaMK-II inhibitors (KN-93 or myr-AIP) or CD29 exhibited shortened neurites 
and a decrease in activated CaMK-II (Figure 3). Taken together, these results indicate that 
CaMK-II is activated in response to β1 integrin engagement with either FN (in fibroblast 
cells) or laminin (in P19 neurons).  
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Figure 1. Disruption of the FN/β1 interaction reduces CaMK-II Activation. (A) 
Effects of integrin β1 blocking on cell attachment. NIH/3T3 cells were sub-cultured on 1 
µg/ml FN or on 1 µg/ml laminin for 3 hours in the presence of the indicated compound. 
Scale bar, 20 µm. (B) Integrin β1 blocking reduces CaMK-II activity. % CaMK-II 
activation was determined in cell lysates as the percentage of total (+Ca2+) activity that is 
Ca2+ independent (-Ca2+). Samples tested represent mean values ± SD from 3 separate 
experiments performed in triplicate.  
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Figure 2. Anti-β1 integrin inhibits CaMK-II activation. Embryoid bodies were cultured 
on laminin for 22 hours, treated for 2 hours and then harvested. CaMK-II enzymatic 
activity was measured in cell lysates of uninduced (non-retinoic acid treated) P19 
embryonal carcinoma cells and of induced (retinoic acid treated) P19 neurons after 
treatment with 5 µM myr-AIP, 5 µM KN-93, 5 µM KN-92, and 10 µg/ml of the CD29 anti-
β1 integrin antibody. Percent CaMK-II activation represents Ca2+ independent activity as a 
percentage of Ca2+-dependent activity. Samples tested represent mean values ± SD from 3 
separate experiments performed in triplicate. 
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Figure 3. Anti-β1 integrin reduces active CaMK-II in collapsed axons. 22 hours after 
plating on laminin, P19 neurons were left untreated (A) or treated with 5 µM KN-93 (B), 5 
µM myr-AIP (C) or 10 µg/ml CD29 (D) for 2 hours. Cultures were then fixed and stained 
with the anti-phospho-Thr287 antibody (phospho-CaMK-II) and representative images from 
3 separate experiments were processed identically. Scale bar represents 50 µm.  
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CHAPTER 2: CaMK-II Promotes Focal Adhesion Disassembly  
 
Cell migration occurs during embryonic development, wound healing, immune 
surveillance and cancer metastasis and involves dozens of molecular players 
(Lauffenburger and Horwitz 1996; Ridley et al. 2003). Essential to cell migration is the 
formation and turnover of structures known as focal adhesions. Focal adhesions are critical 
signaling and structural hubs found in migrating cells (Huttenlocher et al. 1995; 
Lauffenburger and Horwitz 1996; Ridley et al. 2003) which assemble in response to the 
interaction of extracellular matrix ligands with integrin receptors (Huttenlocher et al. 1995; 
Lauffenburger and Horwitz 1996; Ridley et al. 2003).  
Integrin engagement with the extracellular matrix stimulates the tyrosine 
phosphorylation of key cytoskeletal proteins, beginning with FAK autophosphorylation on 
Y397 (Mitra et al. 2005). FAK autophosphorylation recruits src to focal adhesions, and the 
FAK/src complex phosphorylates two adapter proteins, paxillin and p130CAS (Bellis et al. 
1995; Cary et al. 1998; Mitra et al. 2005; Schaller and Parsons 1995; Webb et al. 2004). 
Phosphorylated paxillin and p130CAS recruit proteins, such as Crk, to focal adhesions 
through SH2/SH3 binding domains. Fibroblasts deficient in either FAK or paxillin exhibit 
defects in cell migration (Hagel et al. 2002; Ilic et al. 1995), suggesting that both proteins 
are essential for adhesion dynamics (Webb et al. 2004).  
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Transient elevations in Ca2+ have been shown to induce the disassembly of focal 
adhesions (Conklin et al. 2005; Giannone et al. 2004; Giannone et al. 2002; Marks and 
Maxfield 1990). While calcineurin and calpain have been implicated as Ca2+ targets which 
influence focal adhesion dynamics (Conklin et al. 2005; Franco et al. 2004; Lee et al. 
2005; Shao et al. 2006), the type II Ca2+/calmodulin-dependent protein kinase (CaMK-II) 
has also emerged as a potential target of fibronectin (FN)-induced Ca2+ transients 
(Blystone et al. 1999; Illario et al. 2005).  
CaMK-II is encoded by four genes (α, β, γ, and δ) to yield over three dozen splice 
variants (Tombes et al. 2003), some of which interact with the actin cytoskeleton (Easley et 
al. 2006; Faison et al. 2002; Fink et al. 2003; Lin et al. 2004; Shen et al. 1998). CaMK-II 
has been shown to influence cell motility during embryogenesis and in cultured 
mammalian cells. Morphogens encoded by certain members of the wnt gene family 
activate CaMK-II and lead to convergent extension cell movements during and after 
gastrulation (Kohn and Moon 2005; Kuhl et al. 2000; Sheldahl et al. 2003). CaMK-II is 
also necessary for the attachment and motility of human mammary epithelial cells (HME), 
Chinese hamster ovary cells (CHO) and vascular smooth muscle cells (VSM) (Bilato et al. 
1997; Bouvard and Block 1998; Bouvard et al. 1998; Lundberg et al. 1998; Pauly et al. 
1995; Pfleiderer et al. 2004; Suzuki and Takahashi 2003), and has been implicated in 
integrin cross-talk (Blystone et al. 1999). While these studies emphasize the importance of 
CaMK-II in cell motility, the mechanism by which CaMK-II influences motility and 
adhesion dynamics remains unknown. 
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To define the mechanism by which CaMK-II influences NIH/3T3 fibroblast cell 
motility, GFP-tagged wild type and constitutively active CaMK-IIs were used in 
conjunction with membrane permeant CaMK-II inhibitory drugs in localization, motility 
and focal adhesion assays. Even though a direct substrate has not been identified, the 
results of this study indicate that CaMK-II catalytic activity promotes focal adhesion 
disassembly and detachment from the extracellular matrix by inducing the tyrosine 
dephosphorylation of focal adhesion proteins, thus enabling cell motility.  
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Materials and Methods 
 
NIH/3T3 culture and harvesting- NIH/3T3 cells were cultured on tissue culture dishes 
(Nunc, Rochester NY) at 37˚C in DMEM with 10% fetal bovine serum (FBS; Invitrogen, 
Carlsbad CA). Cells were sub-cultured every 3 to 4 days, never exceeding 95% 
confluency. When specified, dishes were pre-incubated with 1 µg/ml human fibronectin 
(Invitrogen) in PBS (Phosphate Buffered Saline) for 1 hour at 37˚C or overnight at 4˚C, 
washed once with PBS and then placed into DMEM/10% FBS just prior to plating cells. 
Cells were harvested by trypsinization, washed in ice-cold PBS and then resuspended in 
homogenization buffer, which consisted of 30 mM Hepes pH 7.4, 20 mM MgCl2, 80 mM 
β-glycerol phosphate, 2.6 mM EGTA, 0.1 µM okadaic acid, 1 µg/ml each chymostatin, 
leupeptin, antipain, pepstatin and soybean trypsin inhibitor. Cells were lysed using two 
four-second bursts from a probe sonicator (Misonix, Farmingdale NY) and then 
centrifuged at 12,000 x g for 15 minutes at 4˚C.  
 
Plasmid Constructs- EGFP-linked CaMK-II constructs used in this study were prepared as 
previously described (Lantsman and Tombes 2005). EGFP-paxillin, dsRed-paxillin and 
EGFP-FAK were prepared as described (Brown et al. 2006; Webb et al. 2004). EGFP-talin 
and vinculin were generous gifts from Dr. Kenneth Yamada, National Institutes of Health, 
Bethesda MD and Dr. Benjamin Geiger, Weizmann Institute of Science, Rehovot Israel, 
respectively.  
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Transfection and Microscopy- Freshly sub-cultured cells were transfected with 
Lipofectamine 2000 as specified (Invitrogen). Live or formaldehyde fixed cells were 
imaged in phase contrast, traditional fluorescence (Fm) or Total Internal Reflection 
Fluorescence microscopy (TIRFm) using an IX-70 inverted microscope equipped with a 
12-bit black/white F-View CCD camera and processed using Microsuite-B3SV Version 
3.2 software (Olympus, Melville NY). TIRF Illumination utilized a 10mW Argon-ion laser 
(Melles Griot, Carlsbad CA) for 488nm illumination via a 60X/1.45NA PlanApo objective 
(Olympus). Living cells were maintained at 37˚C using a stage heater (20/20 Technology 
Inc., Wilmington NC)  
 
Analysis of Cell Migration, Spreading and Focal Adhesion Size- NIH/3T3 cells were 
cultured to confluency and then scratch-wounded using a single stroke from a fine pipette 
tip. Cells were immediately re-fed with fresh 10% FBS/DMEM containing either vehicle 
alone, 10 µM KN-93 or 20 µM myr-AIP. Cells were then imaged under phase contrast at 0, 
3 and 6 hours post wounding. The microscope stage was maintained at 37˚C. Between 
imaging sessions, cells were returned to the incubator. Cell migration rates were calculated 
from images taken 1 and 4 hours after plating on FN with Microsuite-B3SV Version 3.2 
software (Olympus). Diameter measurements for cell spreading and focal adhesion size 
analysis were also computed with Microsuite-B3SV Version 3.2 software. Minimum and 
maximum threshold values for focal adhesion size were 1.7 µm2 and 35 µm2, respectively. 
Student’s T-tests were used for statistical analysis where significance is indicated. 
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Immunoblotting- Transfected NIH/3T3 cells were harvested as described above (see Cell 
Culture and Harvesting). Immunoblots were blocked with 5% BSA, TBSTA containing 
5% goat serum. Blots were then incubated overnight with 1 µg/ml primary antibody in 5% 
BSA, TBSTA. After a 2 hour incubation with 2 µg/ml alkaline phosphatase conjugated 
secondary antibodies, blots were developed with 0.25 mg/ml BCIP/NBT (Roche, 
Indianapolis IN) in phosphatase buffer (Lantsman and Tombes 2005).  
 
Reagents- Total FAK and paxillin antibodies were obtained from BD Biosciences 
(Rockville, MD), phospho-Y31 paxillin and phospho-S843 FAK antibodies from 
Biosource/Invitrogen, and phospho-Y925 FAK antibody from Cell Signaling Technology 
(Danvers, MA). All secondary antibodies were obtained from Jackson ImmunoResearch 
Laboratories (West Grove, PA). KN-93 (CalBiochem, La Jolla, CA) is a calmodulin 
antagonist, specific for a subset of CaM kinases including CaMK-II, CaMK-I and CaMK-
IV (Hidaka and Ishikawa 1992; Sumi et al. 1991). However, CaMK-I and CaMK-IV were 
undetectable in NIH/3T3 cells as determined using immunological methods (data not 
shown). KN-93 inhibits CaMK-II by 50% at approximately 2 µM and by 90% at 10 µM in 
these cells (Tombes et al. 1995). Myristoylated autoinhibitory peptide 
(KKALRRQEAVDAL) is based on the CaMK-II autoinhibitory domain (Laabich and 
Cooper 2000). Myr-AIP inhibits purified CaMK-II by 90% at 20 µM (data not shown) and 
was obtained from Biomol (Plymouth Meeting, PA). 
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Results 
 
CaMK-II Inhibition Accelerates Cell Spreading on Fibronectin. Fibronectin (FN) 
binding to β1 integrin has been shown to induce localized transient Ca2+ elevations 
(Praetorius et al. 2004), which activate CaMK-II (Blystone et al. 1999; Illario et al. 2005). 
To assess whether CaMK-II activity is necessary for cell spreading, two mechanistically 
distinct CaMK-II inhibitors, myr-AIP (myristoylated autoinhibitory peptide) and KN-93 
were used. Myr-AIP directly blocks catalytic activity while KN-93 antagonizes CaM 
binding and thus prevents activation. NIH/3T3 cells were sub-cultured onto 1 µg/ml FN in 
medium alone (Figure 4A), 20 µM myr-AIP (Figure 4B), or 10 µM KN-93 (Figure 4C) 
and imaged at 0, 5, 10, 15, 30, 45 and 60 minutes post plating on FN. Cells treated with 
either KN-93 or myr-AIP spread more rapidly than untreated cells as shown at 30, 45 and 
60 minutes. KN-92, an inactive analog of KN-93, had no effect on spreading (data not 
shown). The degree of spreading was quantified by averaging cell diameters (n > 100) for 
each condition, and treatment with either KN-93 or myr-AIP significantly accelerated 
spreading after 30 minutes (p < 0.01) (Figure 4D). This effect of CaMK-II inhibition on 
cell spreading was dependent on FN as cells cultured on laminin, or untreated dishes, 
attached slowly and exhibited no sensitivity to KN-93 or myr-AIP treatment. 
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CaMK-II Inhibition Reduces Cell Motility. Mechanical wounding of confluent 
cells has previously been shown to increase cytosolic Ca2+ levels in cells along the edge of 
the wound (Tran et al. 1999), which may activate CaMK-II to induce cell migration. To 
evaluate whether CaMK-II inhibition influences this cell motility, NIH/3T3 cells were 
scratch-wounded and immediately treated with fresh medium containing vehicle alone, 20 
µM myr-AIP or 10 µM KN-93. Cells were then imaged 0, 3 and 6 hours post wounding. 
Cells treated with myr-AIP or KN-93 retained a sizeable wound after 6 hours while cells 
treated with vehicle alone exhibited >70% wound closure (Figure 5).  
 
CaMK-II Localizes to the Surface of Motile NIH/3T3 cells. Because CaMK-II 
inhibition profoundly affected cell spreading and motility, Total Internal Reflection 
Fluorescence microscopy (TIRFm) was used to examine whether CaMK-II localizes to the 
cell surface. NIH/3T3 cells were transfected with GFP-tagged δC CaMK-II and then sub-
cultured onto FN-coated glass coverslips. Conventional fluorescence (Fm) confirmed the 
perinuclear distribution of δC, as previously reported in these cells (Caran et al. 2001; 
Tombes et al. 1999). TIRFm of the same cell indicated that a substantial portion of δC 
CaMK-II localizes to the cell surface (Figure 6A). Time-lapse TIRFm demonstrated that 
CaMK-II is dynamically enriched at the leading edge of a migrating cell and in discrete 
patterns throughout the cell (video not included). This novel, dynamic surface localization 
supports a role for CaMK-II in adhesive and migratory events. 
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Constitutively Active CaMK-II Causes Cell Rounding and Inhibits Cell Motility. 
CaMK-II can be made constitutively active through a phosphomimetic point mutation 
(T287D) in the autoinhibitory domain (Johnson et al. 2000). To test the effects of 
constitutively active CaMK-II on cell motility, cells were transfected with GFP-tagged 
constitutively active (CON) δC CaMK-II, sub-cultured on FN-coated glass coverslips and 
imaged using Fm and TIRFm (Figure 6B). Cells transfected with CON CaMK-II exhibited 
a rounded morphology and lacked the discrete surface localization observed with WT 
CaMK-II (Figure 6). These cells also failed to migrate on FN (video not included).  
 
Both constitutive activation and inhibition of CaMK-II disrupt cell motility. To 
further assess the effect of CON CaMK-II expression and CaMK-II inhibition on cell 
migration, NIH/3T3 cells were transfected with either WT or CON δC CaMK-II and sub-
cultured on FN-coated coverslips. Also, untransfected cells were sub-cultured on FN in the 
presence or absence of CaMK-II inhibitors as indicated (Figure 7). After incubation on FN 
for 1 hour, cells were imaged under phase contrast to track cell migration over a 3 hour 
time-course (n > 15 cells for each condition). Cells expressing CON CaMK-II or treated 
with CaMK-II inhibitors showed a significant reduction in cell migration rates as 
compared to either untreated control cells or cells expressing WT CaMK-II, respectively (p 
< 0.01) (Figure 7).   
 
Constitutively Active CaMK-II Disrupts Paxillin Incorporation into Focal 
Adhesions. Because CaMK-II localizes to the cell surface and influences cell spreading 
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and motility, the effect of CaMK-II activity on focal adhesion proteins was next evaluated. 
Due to the fact that CON CaMK-II expressing cells loosely adhere to FN, GFP-linked 
focal adhesion proteins were used in place of endogenous immuno-localization. Thus, cells 
co-transfected with non-fluorescent WT or CON δC CaMK-II and GFP-tagged focal 
adhesion proteins (paxillin, FAK, vinculin or talin) were sub-cultured on FN-coated 
coverslips for 3 hours and then imaged using conventional fluorescent microscopy. WT 
CaMK-II expressing cells exhibited robust adhesions as visualized with each of the four 
focal adhesion proteins (Figure 8). In contrast, cells expressing CON CaMK-II exhibited a 
near-complete loss of paxillin-containing focal adhesions, while FAK, vinculin and talin 
remained localized to focal adhesions. Paxillin was re-incorporated into focal adhesions 
when cells expressing CON CaMK-II were sub-cultured on FN in the presence of 20 µM 
myr-AIP (CON/myr-AIP). Because paxillin was preferentially, but reversibly eliminated 
from focal adhesions in cells expressing CON CaMK-II, the rate of paxillin recovery to 
focal adhesions after myr-AIP treatment was assessed in single cells using GFP-paxillin 
time lapse microscopy. Adjacent non-transfected and transfected (CON CaMK-II and 
GFP-paxillin) cells were imaged under phase contrast and conventional fluorescent 
microscopy before and 60, 120 and 180 minutes after treatment with 20 µM myr-AIP 
(Figure 9A). Before treatment, the transfected cell was rounded and lacked detectable 
paxillin-containing adhesions but exhibited GFP-paxillin fluorescence within the cytosol. 
Within 1 hour of myr-AIP treatment, paxillin re-incorporated into focal adhesions (Figure 
9A), suggesting that CaMK-II inhibition rapidly influenced paxillin localization.  To 
further illustrate the specific effect of CON CaMK-II on paxillin localization to focal 
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adhesions, NIH/3T3 cells were transfected with non-fluorescent CON δC CaMK-II, 
vinculin-GFP and dsRed-paxillin, sub-cultured on 1 µg/ml FN and then imaged directly 
before and 1 hour after treatment with 20 µM myr-AIP. Within 1 hour treatment of myr-
AIP, paxillin co-localized with vinculin in focal adhesions at the periphery of the cell (see 
arrowheads, Figure 9B). These results suggest that CaMK-II activity specifically affects 
paxillin incorporation into focal adhesions. 
 
Inhibition of Endogenous CaMK-II Increases the Size of Paxillin-GFP Labeled 
Focal Adhesions. The influence of endogenous CaMK-II activity on paxillin-containing 
focal adhesions was next evaluated. Cells were transfected with GFP-paxillin alone and 
sub-cultured on FN for 3 hours in the presence or absence of 20 µM myr-AIP. Compared 
to untreated cells (Figure 10A), treatment with myr-AIP increased the size of GFP-paxillin 
adhesions (Figure 10B). Focal adhesion size was quantified for each condition (n > 600 
focal complexes) and confirmed this distinct shift to larger focal adhesions in cells treated 
with myr-AIP (Figure 10C). Furthermore, the effects of myr-AIP treatment were specific 
to paxillin as FAK, vinculin and talin showed no significant change in focal adhesion size 
in the presence of myr-AIP (Figure 10D). Thus, the inhibition of CaMK-II disrupts cell 
motility by stabilizing paxillin localization to focal adhesions whereas constitutively active 
CaMK-II blocks cell motility by destabilizing paxillin localization.  
  
Constitutively Active CaMK-II Decreases Phospho-tyrosine Levels on FAK and 
Paxillin. β1 integrin-mediated cell attachment stimulates a series of tyrosine 
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phosphorylations on adhesion proteins, which form phosphorylated SH2 and SH3 domains 
necessary for focal adhesion assembly (Bellis et al. 1995; Cary et al. 1998; Mitra et al. 
2005; Schaller and Parsons 1995). In particular, tyrosine phosphorylation of FAK on Y925 
and paxillin on Y31 promotes focal adhesion assembly (Bellis et al. 1995; Schlaepfer et al. 
2004; Sieg et al. 2000). Because CaMK-II activity disrupted paxillin incorporation into 
focal adhesions, we evaluated whether CaMK-II influences tyrosine phosphorylation of 
FAK and paxillin by co-transfecting GFP-FAK or GFP-paxillin with either WT or CON 
CaMK-II. After sub-culturing transfected cells on FN for 3 hours either with or without 20 
µM myr-AIP, as described above, GFP-FAK and paxillin lysates were probed with 
residue-specific phospho-tyrosine antibodies (Figure 11A, B). CON CaMK-II expression 
significantly reduced FAK phospho-Y925 relative to the level in cells transfected with WT 
CaMK-II, but did not impair FAK autophosphorylation (Y397). Similarly, CON CaMK-II 
expression significantly decreased paxillin Y31 phosphorylation (Figure 11A, B). FAK Y925 
and paxillin Y31 phospho-tyrosine levels were partially restored when CON CaMK-II 
expressing cells were treated with 20 µM myr-AIP (CON/myr-AIP) (Figure 11A, B). 
To determine the effects of CaMK-II activity on endogenous FAK and paxillin tyrosine 
levels, NIH/3T3 cells were sub-cultured on FN for three hours in the presence of either 
vehicle control, 10 µM KN-93 or 20 µM myr-AIP (Figure 11C). Inhibition of CaMK-II 
induced a slight increase in Y925 phosphorylation on FAK and Y31 on paxillin as compared 
to vehicle control cells without affecting total expression levels of FAK and paxillin 
(Figure 11C). Taken together, these results indicate that CaMK-II promotes focal adhesion 
disassembly by stimulating tyrosine dephosphorylation of FAK and paxillin.
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Figure 4. CaMK-II inhibition accelerates cell spreading. NIH/3T3 cells were plated on 
1 µg/ml FN and treated with vehicle alone (A), 20 µM myr-AIP (B) and 10 µM KN-93 
(C). Cells were live-imaged under phase contrast at 0, 5, 10, 15, 30, 45 and 60 minutes post 
plating as indicated. Scale bar, 50 µm. (D) Graphical representation of diameter 
measurements from cells imaged at each time point for each condition. n > 100 for each 
condition and each time point. Results obtained are representative of 3 different 
experiments. 
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Figure 5. CaMK-II inhibition reduces the rate of wound closure. A confluent 
monolayer of cells was scratch-wounded and then imaged at 0, 3 and 6 hours in the 
presence of vehicle alone, 20 µM myr-AIP or 10 µM KN-93. Scale bar, 200 µm. Images 
shown are representative from 3 separate experiments. 
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Figure 6. CaMK-II is dynamically localized at the surface of motile fibroblasts. 
NIH/3T3 cells were transfected with either GFP-labeled wild-type δC CaMK-II (A) or 
constitutively active (CON) δC CaMK-II (B) and sub-cultured on 1 µg/ml FN for 3 hours. 
Cells were fixed and imaged using traditional fluorescence microscopy (Fm) and total 
internal reflection fluorescence microscopy (TIRFm). Scale bar, 50 µm.  
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Figure 7. Both CaMK-II inhibition and expression of constitutively active CaMK-II 
block cell motility. NIH/3T3 cells were transfected with either GFP-labeled wild-type or 
CON δC CaMK-II and sub-cultured on 1 µg/ml FN for 1 hour. Similarly, untransfected 
NIH/3T3 cells were sub-cultured on FN in the presence or absence of the indicated CaMK-
II inhibitor. After incubation on FN for 1 hour, cells were imaged under phase contrast 
over a 3 hour time-course. Migration rates (in microns/hour) were determined using 
Olympus Microsuite software. * p < 0.01 compared to Untreated. # p < 0.01 compared to 
WT. 
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Figure 8. Constitutively active CaMK-II impairs focal adhesion formation. NIH/3T3 
cells were co-transfected with either unlabeled wild-type or CON δC CaMK-II and the 
indicated GFP-tagged protein. Cells were sub-cultured on 1 µg/ml FN for 3 hours in the 
presence or absence of 20 µM myr-AIP, fixed and imaged under traditional fluorescence 
microscopy. Scale bar, 50 µm. 
 
 
 
 
 
 
 
  45 
 
 
 
 
  46 
 
 
 
 
 
Figure 9. Inhibition of constitutively active CaMK-II restores paxillin-containing 
complexes within 1 hour.  (A) NIH/3T3 cells were co-transfected with unlabeled CON δC 
CaMK-II and GFP-paxillin. Cells were plated on 1 µg/ml FN for 3 hours, then re-fed with 
medium containing 20 µM myr-AIP. Cells were then imaged under phase contrast and 
traditional fluorescence microscopy at 0, 60, 120 and 180 minutes post treatment. Inset 
images represent the lower right-hand corner of the transfected cell. Scale bar, 50 µm. (B) 
NIH/3T3 cells were transfected with unlabeled CON δC CaMK-II, vinculin-GFP and 
dsRed-paxillin and sub-cultured on FN for 3 hours. Cells were then imaged under 
traditional fluorescent microscopy directly before and 1 hour after treatment with 20 µM 
myr-AIP. Arrowheads indicate regions of interest where treatment of myr-AIP induces 
increased paxillin localization to the cell periphery and enhanced co-localization with 
vinculin-GFP. Scale bar, 10 µm.  
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Figure 10. Inhibition of endogenous CaMK-II enlarges paxillin-containing complexes. 
NIH/3T3 cells were transfected with GFP-paxillin, sub-cultured on 1 µg/ml FN for 3 hours 
in the presence of vehicle alone (A) or 20 µM myr-AIP (B) and imaged with traditional 
fluorescence microscopy. Scale bar, 50 µm. (C) The area of each GFP-paxillin adhesion 
(from >10 cells and > 600 adhesions for each condition) was calculated. The minimum 
area for focal adhesions was 1.7 µm2, and maximum was 35 µm2. (D) Graphical 
representation of average focal adhesion size of NIH/3T3 cells transfected with either 
GFP-labeled paxillin, FAK, vinculin or talin and sub-cultured on 1 µg/ml FN for 3 hours in 
the presence or absence of 20 µM myr-AIP.  
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Figure 11. Constitutively active CaMK-II decreases phospho-tyrosine levels on FAK 
and paxillin. (A) NIH/3T3 cells were co-transfected with GFP-FAK or GFP-paxillin and 
either wild-type (WT) δC CaMK-II or constitutively active (CON) δC CaMK-II and sub-
cultured on 1 µg/ml FN for 3 hours. Cells expressing CON δC CaMK-II/GFP-FAK or GFP-
paxillin were treated with vehicle alone or with 20 µM myr-AIP during sub-culture (as 
indicated). GFP-FAK and GFP-paxillin lysates were then probed with the indicated 
phospho or total antibody. (B) Densitometry from 3 different immunoblots for FAK Y925 
and paxillin Y31. (C) NIH/3T3 cells were sub-cultured on 1 µg/ml FN for 3 hours in the 
presence of either vehicle control, 10 µM KN-93 or 20 µM myr-AIP. Cells were harvested 
and probed with the indicated antibodies.  
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CHAPTER 3: Protein Targets Downstream of CaMK-II Activity 
 
The results presented thus far provide the first direct evidence of a link between 
CaMK-II activity and focal adhesion turnover as a means of influencing cell adhesion and 
motility. Previous studies have shown that CaMK-II influences de-adhesion by disrupting 
β1 integrin clustering through either direct phosphorylation of β1 integrin (Takahashi 
2001; Wennerberg et al. 1998) or phosphorylation of integrin cytoplasmic associated 
protein-1 alpha, ICAP-1α (Blystone et al. 1999). However, many cell types, including 
NIH/3T3 embryonic fibroblasts, lack ICAP-1α (Bouvard et al. 2003). Furthermore, β1 
integrin engagement, which induces FAK autophosphorylation (Mitra et al. 2005), was not 
affected by CON CaMK-II expression or CaMK-II inhibition. Our results are consistent 
with previous findings implicating Ca2+ transients with focal adhesion disassembly 
(Conklin et al. 2005) and reveal a novel means by which CaMK-II influences focal 
adhesion turnover by transiently promoting the tyrosine dephosphorylation of both FAK 
and paxillin.   
While we have demonstrated a unique role for CaMK-II in focal adhesion turnover, 
the relevant substrate has not been determined. Although CaMK-II has been implicated in 
the phosphorylation of FAK on S843 within minutes of G-protein receptor activation (Fan et 
al. 2005), the phosphorylation status of FAK S843 was not altered upon CaMK-II 
overexpression or inhibition. Therefore it is not likely that CaMK-II directly 
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phosphorylates FAK under the conditions described here. Rather, the reduction in FAK 
and paxillin phospho-tyrosine levels caused by constitutively active CaMK-II is most 
consistent with the activation of a tyrosine phosphatase.  
The most likely candidate tyrosine phosphatase downstream of CaMK-II activity is 
the SH2 domain-containing protein tyrosine phosphatase 2 (SHP-2), also known as 
PTPN11 or PTP1D. CaMK-II has been implicated upstream from SHP-2 in T-cell 
signaling (McGargill et al. 2005), but this link has not been investigated with respect to 
cell motility and/or focal adhesion turnover. SHP-2, a non-receptor tyrosine phosphatase, 
translocates from the ER to focal adhesions in response to src signaling (Wang et al. 2006) 
to dephosphorylate FAK on Y925 and paxillin on Y31, thus promoting detachment from the 
extracellular matrix (Vadlamudi et al. 2002). Like CaMK-II inhibition, the knockout or 
inhibition of SHP-2 increases focal adhesion size and blocks cell motility in both cells in 
culture and in mouse embryos (Inagaki et al. 2000; MacGillivray et al. 2003; Manes et al. 
1999; Saxton et al. 2000; Wang et al. 2005; Yu et al. 1998). While SHP-2 activity is 
known to be regulated by tyrosine phosphorylation, this enzyme can also be 
phosphorylated on serine/threonine residues (Poole and Jones 2005).  
In this study, we evaluated potential CaMK-II substrates involved in focal adhesion 
dynamics. Based on previous results and sequence analysis, we tested the ability of CaMK-
II to phosphorylate 8 different proteins found to influence focal adhesions. To further link 
SHP-2 in a novel pathway downstream of CaMK-II activation, we used dominant/negative 
and constitutively active mutant SHP-2 constructs in conjunction with constitutively active 
CaMK-II to visualize effects on paxillin-containing focal adhesions. The results of this 
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study suggest that CaMK-II elevates SHP-2 phosphatase activity by inducing tyrosine 
phosphorylation of Gab1, a protein that activates SHP-2.  
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Materials and Methods 
 
NIH/3T3 culture and harvesting- NIH/3T3 cells were cultured on tissue culture dishes 
(Nunc, Rochester NY) at 37˚C in DMEM with 10% fetal bovine serum (FBS; Invitrogen, 
Carlsbad CA). Cells were sub-cultured every 3 to 4 days, never exceeding 95% 
confluency. When specified, dishes were pre-incubated with 1 µg/ml human fibronectin 
(Invitrogen) in PBS (Phosphate Buffered Saline) for 1 hour at 37˚C or overnight at 4˚C, 
washed once with PBS and then placed into DMEM/10% FBS just prior to plating cells. 
Cells were harvested by trypsinization, washed in ice-cold PBS and then resuspended in 
homogenization buffer, which consisted of 30 mM Hepes pH 7.4, 20 mM MgCl2, 80 mM 
β-glycerol phosphate, 2.6 mM EGTA, 0.1 µM okadaic acid, 1 µg/ml each chymostatin, 
leupeptin, antipain, pepstatin and soybean trypsin inhibitor. Cells were lysed using two 
four-second bursts from a probe sonicator (Misonix, Farmingdale NY) and then 
centrifuged at 12,000 x g for 15 minutes at 4˚C.  
 
Plasmid Constructs- EGFP-linked CaMK-II constructs used in this study were prepared as 
previously described (Lantsman and Tombes 2005). EGFP-paxillin was prepared as 
described (Brown et al. 2006; Webb et al. 2004). Wild-type SHP-2, dominant/negative 
SHP-2 and constitutively active SHP-2 were all obtained from Addgene (Plasmid numbers 
8381, 8382 and 8321, respectively). EGFP-talin and vinculin were generous gifts from Dr. 
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Kenneth Yamada, National Institutes of Health, Bethesda MD and Dr. Benjamin Geiger, 
Weizmann Institute of Science, Rehovot Israel, respectively. 
 
 
Transfection and Microscopy- Freshly sub-cultured cells were transfected with 
Lipofectamine 2000 as specified (Invitrogen). Live or formaldehyde fixed cells were 
imaged in phase contrast or traditional fluorescence (Fm) using an IX-70 inverted 
microscope equipped with a 12-bit black/white F-View CCD camera and processed using 
Microsuite-B3SV Version 3.2 software (Olympus, Melville NY). Confocal Images were 
acquired with an IX-81 inverted Spinning Disk Confocal microscope equipped with an 
Orcaer monochrome CCD camera and processed using SlideBook Version 4.2 (Olymus). 
 
Immunoprecipitation and Western Blotting- Transfected NIH/3T3 cells were washed once 
with ice-cold PBS and then lysed with a minimal volume of homogenization buffer (see 
Cell Culture and Harvesting) containing 0.1% NP-40 (Pierce) for 30 minutes on ice. Cell 
lysates were scraped into microcentrifuge tubes and sonicated for 2 seconds. Lysates were 
then centrifuged at 12,000 x g for 15 minutes at 4˚C. GFP-tagged FAK was 
immunoprecipitated from 500 µg of total lysate protein for 16 hours at 4˚C. Immuno-
complexes were then incubated for 2 hours with protein G magnetic beads (DynaBeads, 
Carlsbad, CA). Magnetic beads were washed 3 times and resuspended in 2X SDS loading 
buffer with DTT. Proteins were resolved on 10% polyacrylamide gels and then transferred 
to nitrocellulose. Immunoblots were blocked with 5% BSA, TBSTA containing 5% goat 
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serum. Blots were then incubated overnight with 1 µg/ml primary antibody in 5% BSA, 
TBSTA. After a 2 hour incubation with 2 µg/ml alkaline phosphatase conjugated 
secondary antibodies, blots were developed with 0.25 mg/ml BCIP/NBT (Roche, 
Indiannapolis IN) in phosphatase buffer (Lantsman and Tombes 2005).  
 
CaMK-II Phosphorylation Assay- Immunoprecipitated focal adhesion proteins were 
incubated alone, with purified CaMK-II or with CaMK-II and myr-AIP for 30 minutes at 
32°C in buffer containing 30 mM HEPES (pH 7.4), 0.1 mM dithiothreitol, 15 mM 
magnesium acetate, 50 mM β-glycerophosphate, 0.5 mM cyclic AMP dependent protein 
kinase inhibitor peptide, 0.5 mCi of [γ-32P] ATP, 20 mM ATP, 1 mM calmodulin, and 1 
mM EGTA/3 mM CaCl2. Phosphorylation reactions were stopped with an equal volume of 
preheated 2X sample buffer, followed by boiling for 3 minutes. Samples were then 
subjected to SDS-PAGE and transferred to nitrocellulose. Transferred proteins were then 
exposed to X-Blue film (Kodak, Rochester, NY) at -80°C.  
 
Reagents- The GFP immunoprecipitating antibody was from Invitrogen (Carlsbad, CA). 
Immunoprecipitating antibodies for paxillin, FAK, β1 integrin and SHP-2 were all from 
BD Biosciences (San Jose, CA). The Gab1 immunoprecipitating antibody was from Cell 
Signaling (Danvers, MA). Myr-AIP, a peptide mimetic for the autoinhibitory domain of 
CaMK-II, was from Biomol (Plymouth Meeting, PA). Radio-labeled γ-ATP was from 
Perkin Elmer (Waltham, MA). All other chemicals were from Sigma-Aldrich (St. Louis, 
MO). 
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Results 
 
Myr-AIP Treatment Cannot Recover CON CaMK-II-induced Cell Rounding in 
Cells Expressing SHP-2 CON. Because expression of CON CaMK-II induced tyrosine 
dephosphorylation of sites on FAK and paxillin, we evaluated whether the SH2-domain 
containing tyrosine phosphatase 2 (SHP-2) lies downstream of CaMK-II activity. To assess 
the effects of constitutively active SHP-2 (SHP-2 CON) on cell morphology and paxillin-
containing focal adhesions, NIH/3T3 cells were transfected with GFP-tagged paxillin, 
unlabeled CON CaMK-II and either empty vector or unlabeled SHP-2 CON. 24 hours after 
transfection, cells were sub-cultured on 1µg/ml FN for three hours, formaldehyde-fixed 
and imaged under spinning disk confocal microscopy (Figure 12). As previously shown, 
cells expressing CON CaMK-II failed to spread on FN and showed a near elimination of 
paxillin-containing focal adhesions. This phenotype was recovered when CON CaMK-II 
expressing cells were cultured in the presence of 20 µM myr-AIP (Figure 12). Similarly, 
cells expressing both CON CaMK-II and SHP-2 CON showed a rounded cell morphology 
and a loss of paxillin-containing focal adhesions. However, focal adhesions and cell 
spreading could not be recovered in cells expressing both CON CaMK-II and SHP-2 CON 
(Figure 12). These results suggest that SHP-2 CON induces effects on cell morphology and 
focal adhesions similar to that of CON CaMK-II and that myr-AIP cannot recover the 
SHP-2 CON mutant phenotype. 
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Expression of Dominant/negative SHP-2 Partially Reverses the CON CaMK-II 
Phenotype. To further demonstrate that SHP-2 lies downstream of CaMK-II, NIH/3T3 
cells were transfected with GFP-tagged paxillin, unlabeled CON CaMK-II and either 
empty vector or dominant/negative SHP-2 (D/N SHP-2). 24 hours after transfection, cells 
were plated on FN for 3 hours, fixed and imaged using traditional fluorescence microscopy 
(Figure 13). Cells expressing CON CaMK-II/empty vector were rounded and showed a 
loss of paxillin-containing focal adhesions (Figure 13). Cells expressing D/N SHP-2 still 
retained a more rounded cell morphology, but these cells exhibited a strong increase 
paxillin-containing focal adhesions at the periphery of the cell (Figure 13). These results 
suggest that SHP-2 lies downstream of CaMK-II activation in causing focal adhesion 
turnover.   
 
CaMK-II Does Not Phosphorylate SHP-2 in vitro. Previous results suggested that 
CaMK-II might influence SHP-2 activity directly. To determine whether CaMK-II could 
phosphorylate SHP-2, immunopurified SHP-2 was used as a substrate in a CaMK-II 
phosphorylation assay. Sequence analysis of SHP-2 reveals 10 CaMK-II consensus 
sequences (Figure 14). To test whether these sites are phosphorylated in native SHP-2, 
immunoprecipitated SHP-2 (from NIH/3T3 cells) was incubated with purified CaMK-II 
for 30 minutes at 32◦C in CaMK-II kinase specific buffer. As a control, SHP-2 was 
incubated without CaMK-II, and to show specificity, a third condition contained SHP-2 
and CaMK-II incubated with 50 µM myr-AIP. Table 1 shows the results of several 
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different trials with 8 different focal adhesion proteins, including SHP-2 These results 
suggest that CaMK-II was unable to phosphorylate SHP-2 and other focal adhesion 
proteins in vitro. Our results showing an inability to phosphorylate SHP-2 with CaMK-II 
are similar to difficulties in other studies implicating SHP-2 downstream of CaMK-II 
(McGargill et al. 2005).   
 
CON CaMK-II Expression Increases Tyrosine Phosphorylation of Gab1 on Y627. 
Because CaMK-II does not appear to affect SHP-2 activity directly, we next evaluated 
whether CaMK-II influenced the tyrosine phosphorylation levels of Gab1, a protein known 
to bind SHP-2 and induce its activation (Cunnick et al. 2001). Specifically, Y627 is a 
critical phosphorylation site necessary for SHP-2 activation. This residue can be 
phosphorylated by src family kinases, but also possibly c-abl, as Gab1 recruits c-abl to the 
plasma membrane (Holgado-Madruga et al. 1996). To evaluate Gab1 phosphorylation, 
cells were transfected with either GFP-WT CaMK-II or GFP-CON CaMK-II. 24 hours 
post transfection, cells were sub-cultured on FN with or without 20 µM myr-AIP as 
indicated for three hours and harvested. Lysates were then probed with phospho-Y627 and 
total Gab1 antibodies. Cells expressing CON CaMK-II exhibited a significant increase in 
Gab Y627 phosphorylation as compared to WT expressing cells, and this increase was 
diminished when CON CaMK-II expressing cells were sub-cultured in the presence of 
myr-AIP (Figure 15). While CaMK-II cannot phosphorylate Gab1 directly (Table 1), these 
results indicate that CaMK-II influences SHP-2 activation by stimulating Gab1 tyrosine 
phosphorylation through an unknown mechanism.  
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c-abl Inhibition Rescues CON CaMK-II-induced Cell Rounding and Focal 
Adhesion Disassembly. As previously mentioned, c-abl is a tyrosine kinase involved in 
cell motility and binds to Gab1 (Hernandez et al. 2004; Holgado-Madruga et al. 1996). c-
abl is activated by tyrosine phosphorylation by src family kinases, but may be regulated by 
serine/threonine phosphorylation as well (Hernandez et al. 2004) (and unpublished data, 
see Cell Signaling c-abl product information). To determine whether c-abl is downstream 
of CaMK-II, NIH/3T3 cells were transfected with GFP-tagged paxillin and either unlabled 
WT or CON CaMK-II. 24 hours after transfection, cells were sub-cultured on FN for 3 
hours, fixed and imaged using traditional fluorescence microscopy. CON CaMK-II 
expressing cells were also sub-cultured in the presence of 20 µM myr-AIP (CON/myr-AIP) 
or 10 µM AG957, a specific c-abl inhibitor also known as tyrphostin (CON/AG957). As 
previously shown, expression of CON CaMK-II induced cell rounding and disrupted 
paxillin-containing focal adhesion formation (Figure 16). Like myr-AIP treatment, 
inhibition of c-abl recovered the CON CaMK-II phenotype by inducing cell spreading on 
FN and re-incorporation of paxillin into focal adhesions (Figure 16). These results strongly 
suggest that c-abl lies downstream of CaMK-II and provide a framework for the 
mechanism by which CaMK-II induces focal adhesion turnover.   
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Figure 12. CaMK-II Inhibition Does Not Rescue SHP-2-mediated Focal Adhesion 
Disassembly. NIH/3T3 cells were transfected with GFP-paxillin, constitutively active 
(CON) CaMK-II, and either vector alone or constitutively active SHP-2 (SHP-2-CON), as 
indicated. Following sub-culture on 1 µg/ml FN for 3 hours with or without 20 µM myr-
AIP, cells were fixed and imaged under spinning disk confocal microscopy. Scale bar, 50 
µm.  
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Figure 13. D/N SHP-2 Expression Partially Reverses CON CaMK-II-mediated Cell 
Rounding.  NIH/3T3 cells were transfected with GFP-paxillin, constitutively active 
(CON) CaMK-II, and either vector alone or dominant/negative SHP-2 (D/N SHP-2), as 
indicated. Following sub-culture on FN for 3 hours cells were fixed and imaged under 
traditional fluorescence microscopy. Scale bar, 50 µm. 
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Figure 14. SHP-2 Contains Several CaMK-II Consensus Sequences. Sequence analysis 
of SHP-2 reveals a number of potential CaMK-II phosphorylation sites.  
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SHP-2 Human Sequence : 10 CaMK-II consensus phosphorylation 
sequences T73, T127, T134, S160, S189, S234, S365, T411, S448, S576 
 
MKSRRWFHPN ITGVEAENLL LTRGVDGSFL ARPSKSNPGD LTLSVRRNGA 
VTHIKIQNTG DYYDLYGGEK FATLAELVQY YMEHHGQLKE KNGDVIELKY 
PLNCADPTSE RWFHGHLSGK EAEKLLTEKG KHGSFLVRES QSHPGDFVLS 
VRTGDDKGES NDGKSKVTHV MIRCQELKYD VGGGERFDSL TDLVEHYKKN 
PMVETLGTVL QLKQPLNTTR INAAEIESRV RELSKLAETT DKVKQGFWEE 
FETLQQQECK LLYSRKEGQR QENKNKNRYK NILPFDHTRV VLHDGDPNEP 
VSDYINANII MPEFETKCNN SKPKKSYIAT QGCLQNTVND FWRMVFQENS 
RVIVMTTKEV ERGKSKCVKY WPDEYALKEY GVMRVRNVKE SAAHDYTLRE 
LKLSKVGQGN TERTVWQYHF RTWPDHGVPS DPGGVLDFLE EVHHKQESIM 
DAGPVVVHCS AGIGRTGTFI VIDILIDIIR EKGVDCDIDV PKTIQMVRSQ 
RSGMVQTEAQ YRSIYMAVQH YIETLQRRIE EEQKSKRKGH EYTNIKYSLA 
DQTSGDQSPL  PPCTPTPPCA EMREDSARVY  ENVGLMQQQK SFR 
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Table 1. Analysis of Potential CaMK-II Targets Involved in Focal Adhesion 
Dynamics. Each target was evaluated by sequence analysis and by CaMK-II in vitro 
phosphorylation assay. Where applicable, citations are listed to indicate previous research 
implicating specific proteins as CaMK-II targets.  
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Target Proteins CaMK-II Able to 
Phosphorylate? 
Evidence For or Against 
Phosphorylation 
Paxillin No No CaMK-II consensus 
sequences 
FAK Yes, Ser843 (Fan et. al. 
2005) 
Yes, but p-Ser843 levels are 
unchanged in our 
experimental approach 
Vinculin No No CaMK-II consensus 
sequences 
Talin No No CaMK-II consensus 
sequences 
β1 Integrin Yes, Ser789 (Takahashi et. 
al 2001 and Wennerberg et. 
al. 1998) 
Yes, but not in our in vitro 
assays, and when 
phosphorylated, blocks 
FAK autophosphorylation 
and talin recruitment to 
focal adhesions 
SHP-2 No Contains CaMK-II 
consensus sequences, but 
cannot be phosphorylated in 
vitro by our lab or 
McGargill et. al. 2005 
Gab1 No No real CaMK-II consensus 
sequences 
c-abl Potentially Contains CaMK-II 
consensus sequences 
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Figure 15. Constitutively active CaMK-II increases the tyrosine phosphorylation of 
Gab1. A. NIH/3T3 cells were transfected with either wild-type (WT) GFP-CaMK-II or 
constitutively active (CON) GFP-CaMK-II and sub-cultured on 1 µg/ml FN for 3 hours. 
Cells expressing CON GFP-CaMK-II were treated with vehicle alone or with 20 µM myr-
AIP during sub-culture (as indicated). Gab1 was then immunoprecipitated from transfected 
lysates and probed with either phospho-Y627 Gab1 or total Gab1. B. Densitometry of p-
Y627 Gab1 from 3 separate experiments, * p < 0.05.  
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Figure 16. c-abl Inhibition Recovers Both Cell Spreading and Paxillin-containing 
Focal Adhesions in Cells Expressing CON CaMK-II. NIH/3T3 cells were transfected 
with GFP-tagged paxillin, and either wild type (WT) or constitutively active (CON) 
CaMK-II. Cells were sub-cultured on FN for 3 hours either without treatment or in the 
presence of 20 µM myr-AIP (CON/myr-AIP) or 10 µM AG957 (CON/AG957). Cells were 
fixed and imaged under traditional fluorescence microscopy. Scale bar, 50 µm. 
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Figure 17. CaMK-II Enables Cell Motility By Activating Tiam1 and Inducing Focal 
Adhesion Turnover. Schematic depicting the dual role for CaMK-II in regulating cell 
motility.  
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Figure 18. A Novel Role for CaMK-II Linking Tyrosine Dephosphorylation of FAK 
and Paxillin with Heart and Limb Development.  This pathway links CaMK-II 
expression and activation through the non-canonical Wnt pathway with focal adhesion 
turnover in promoting proper heart and limb development.  
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General Discussion 
 
Dual Role for CaMK-II in Cell Motility 
 
While the results presented here implicate CaMK-II in a novel pathway regulating 
focal adhesion turnover, CaMK-II has been previously linked to cell motility (Bilato et al. 
1997; Bouvard and Block 1998; Bouvard et al. 1998; Lundberg et al. 1998; Pauly et al. 
1995; Pfleiderer et al. 2004; Suzuki and Takahashi 2003). More recently, CaMK-II has 
been shown to phosphorylate and activate Tiam1 (tumor invasion and metastasis 1), a 
RhoGEF that activates Rac (Fleming et al. 1999; Hamelers et al. 2005). Rac then induces 
actin polymerization and lamellipodial extension at the leading edge of the cell to promote 
cell motility. However, expression of constitutively active Rac enhances both cell 
spreading on FN and cell motility (Kerr et al. 2008). This phenotype is the exact opposite 
of CON CaMK-II expression which leads to decreased cell adhesion (by inducing focal 
adhesion turnover) and decreased cell motility. Thus CaMK-II appears to have a dual role 
in regulating cell motility (Figure 17), in which CaMK-II promotes cell motility by 
activating TIAM1 to drive lamellipodial extension and by activating SHP-2 to induce focal 
adhesion turnover.  
Like CaMK-II both SHP-2 and FAK are critically involved in focal adhesion 
dynamics in that inhibition or knockout of FAK or SHP-2 increase focal adhesion size and 
block cell motility (Ilic et al. 1995; Inagaki et al. 2000; MacGillivray et al. 2003; Manes et 
al. 1999; Saxton et al. 2000; Wang et al. 2005; Yu et al. 1998). Similarly to CON CaMK-
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II, expression constitutively active SHP-2 or FAK also disrupts cell motility (Poole and 
Jones 2005; von Wichert et al. 2003).   Results such as these, which suggest that there are 
optimal activity levels for CaMK-II, SHP-2 and FAK, support common roles for each 
enzyme in promoting the cyclical formation and breakdown of focal adhesions. In this 
context and in order to ensure that focal adhesion disassembly does not occur immediately 
after assembly, Ca2+ elevations must be temporally offset from the initial adhesion event. 
Evidence supports such a model in that talin recruits PIPKIγ (Di Paolo et al. 2002), which 
is activated by src to catalyze the synthesis of the phospholipid, PIP2 (Ling et al. 2003). 
FAK then recruits phospholipase C (PLCγ) to focal adhesions (Mitra et al. 2005), which 
generates IP3 from the patches of PIP2 that accumulate over time at the cell surface (Huang 
et al. 2004). IP3 then stimulates localized Ca2+ release from the ER, which resides near 
focal adhesions and SHP-2 (Wang et al. 2006).   
The results presented here suggest that the attachment of cells to FN triggers focal 
adhesion assembly, which eventually yields a localized, transient Ca2+ release from the ER 
to activate CaMK-II. Activated CaMK-II then indirectly activates a protein tyrosine 
phosphatase SHP-2, through c-abl and Gab1, to dephosphorylate a limited number of 
tyrosine residues on FAK and paxillin, thus promoting focal adhesion turnover. 
Concurrently, CaMK-II activates TIAM1 to induce lamellipodial extension, and this 
process combined with focal adhesion turnover enables cell motility.      
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Role for CaMK-II in Embryonic Development 
 
During early embryonic development, the non-canonical wnt family of morphogens 
activate CaMK-II to drive convergent extension cell migration, an event that occurs during 
and after gastrulation (Kohn and Moon 2005; Kuhl et al. 2000). Also, non-canonical wnts 
have been implicated in both heart and limb development, two processes that require cell 
motility and proliferation (Grandel and Schulte-Merker 1998; Schoenebeck and Yelon 
2007). Results presented here coupled with previous studies implicating CaMK-II in cell 
cycle progression (Morris et al. 1998; Tombes et al. 1995) suggest that CaMK-II is a 
critical signaling protein in both heart and limb development in vertebrates.    
The inability of CaMK-II to phosphorylate SHP-2 in vitro is quite an interesting 
phenomenon given the fact that mutations in some of the CaMK-II consensus sites lead to 
severe defects in both heart and limb formation. Specifically, mutations in certain CaMK-II 
consensus sites lead to defects in heart septation and cause shortened stature in humans, a 
condition referred to as Noonan Syndrome (van der Burgt 2007). Interestingly, inhibition 
of CaMK-II or knockout of the heart and limb specific CaMK-II results in improper heart 
development and a loss of forelimbs (pectoral fins) in zebrafish (Danio rerio) (unpublished 
data, Rothschild, SC, Easley CA, et. al. Tbx5-mediated β2 CaMK-II Expression is 
Required for Heart Looping and Pectoral Fin Development). Like CaMK-II, knockout or 
inactivation of SHP-2 causes pericardial sac enlargement, defects in cardiac looping and 
foreshortened pectoral fins in zebrafish (Jopling et al. 2007; Razzaque et al. 2007). These 
similarities in morphant phenotype link CaMK-II and SHP-2 in a novel pathway in which 
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Tbx5-mediated CaMK-II expression, activated by non-canonical wnts, enables cell 
motility by inducing focal adhesion turnover via SHP-2 activation (Figure 18). 
 
Other Potential Pathways Influenced by CaMK-II 
 
 Along with promoting cell motility, integrin engagement with FN promotes cell 
survival and cell cycle progression through the activation of FAK which in turn elevates 
ERK1/2 levels and activates PI3-K (Walker and Assoian 2005). PI3-K is known to 
promote cell growth, viability and migration through Akt signaling (Cantley 2002). As 
shown in this dissertation, inhibition of CaMK-II enhances cell adhesion, an event that 
should elevate levels of phospho-Akt and phospho-ERK1/2. However, cells treated with 
KN-93 for 24 hours show a significant reduction in both Akt and ERK1/2 phosphorylation 
levels (Appendix C) as determined using BioRad’s Bioplex system. As mentioned, KN-93-
mediated CaMK-II inhibition blocks cell cycle progression by reducing cyclin D levels, 
and this result is similar to those seen by PI3-K inhibition (Cantley 2002). Currently, the 
mechanism by which CaMK-II influences cyclin D expression is unknown, yet the results 
from the Bioplex Assay suggest CaMK-II promotes cell cycle progression through PI3-K 
signaling. Further studies using CON CaMK-II will be conducted to assess the influence of 
CaMK-II activity on PI-3K activation and signaling. 
 
 Another interesting aspect of CaMK-II that pertains to PI-3K signaling is the 
localization of CaMK-II at the cell surface as seen using TIRFm. The major CaMK-II 
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variant expressed in NIH/3T3 cells (and the variant used throughout this dissertation) is the 
simplest form of CaMK-II and contains no domains that would link CaMK-II to the 
plasma membrane. To localize to the cell surface, CaMK-II may bind to Gab1 as reciprocal 
immunoprecipitation studies involving Gab1 and CaMK-II suggest that these proteins 
interact with each other (Appendix D). However, mass spectrometry analysis of CaMK-II 
direct binding partners did not yield Gab1 as a primary interacting protein. Thus Gab1, 
which recruits PI3-K, PLCγ and SHP-2 to focal adhesions, interacts with CaMK-II through 
an unknown adapter protein. Identifying this protein would allow us to explore how 
CaMK-II is targeted to focal adhesions and might allow us to further delineate a role for 
CaMK-II in focal adhesion turnover. Thus from these results, we can suggest that CaMK-II 
is a critical signaling hub that resides at the cell surface to influence cell motility and also 
transduces signals through PI3-K, potentially, to regulate both cell cycle progression and 
cell survival.     
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APPENDIX A 
 
Supplemental Figure 1. CaMK-II Structure. A. Cryo-electron micrograph of CaMK-II. 
B. Linear domain map of CaMK-II. 
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Part A image courtesy of Neal Waxham, Three-dimensional reconstructions of 
calcium/calmodulin-dependent (CaM) kinase IIalpha and truncated CaM kinase 
IIalpha reveal a unique organization for its structural core and functional domains. J. 
Biol. Chem. 2000.    
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APPENDIX B 
 
Supplemental Figure 2. Focal Adhesion Diagram. Schematic of a focal adhesion 
signaling hub.  
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Taken from the Massachusetts Institute of Technology Molecular, Cellular and 
Tissue Biomechanics course information. 
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APPENDIX C 
 
Supplemental Figure 3. CaMK-II Inhibition Reduces Phosphorylation Levels of Both 
Akt and ERK1/2. NIH/3T3 cells were cultured for 24 hours in the presence or absence of 
10 µM KN-93. Cells were then harvested and prepared for the BioRad Bioplex assay 
which measures the ratio of phospho to total protein of selected proteins, which included 
Akt and ERK1/2. Phospho-levels from 3 separate trials were normalized to total protein 
and graphed as shown. Y-axis represents arbitrary units. * indicates statistical significance 
as p < 0.05.   
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APPENDIX D 
 
Supplemental Figure 4. CaMK-II Immunoprecipitates Contain Gab1. A. Endogenous 
CaMK-II was immunoprecipitated from NIH/3T3 cells and probed for Gab1. Likewise, 
Gab1 was immunoprecipitated from cells expressing GFP-labeled CaMK-II and probed for 
CaMK-II. B. Autoradiogram of Gab1 immunoprecipitates indicating that endogenous 
CaMK-II associates with the Gab1. These results were all representative of 3 separate 
experiments.  
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Antibody (Company) Tested Applications Suitability 
CaMK-II (BD Biosciences) IF, WB, IP Worked well in all apps. 
CaMK-II (Cell Signaling) IF, WB, IP Only worked marginally in 
WB 
CaMK-II (Stressgen) IF, WB, IP Worked only in WB, very 
clean antibody 
T286/7 CaMK-II 
(Millipore) 
IF, WB Works well in P19 neurons 
for both WB and IF, but not 
in 3T3 cells 
T286/7 CaMK-II 
(Stressgen) 
WB Seems to work, but only 
tested once 
Gab1 (Cell Signaling) WB, IP Worked well in all apps. 
Y627 Gab1 (Cell Signaling) WB Weak results, would work 
better with GFP-Gab1 
FAK (BD Biosciences) WB, IP Worked well in all apps. 
Y397 FAK (BD 
Biosciences) 
WB Worked well 
Y577/8 FAK (Cell 
Signaling) 
WB Very weak results, would 
not recommend 
Y925 FAK (Cell Signaling) WB Worked well 
Paxillin (BD Biosciences) IP, WB Worked well in all apps. 
Y31 Paxillin (Biosource) WB Worked well 
SHP-2 (BD Biosciences) WB, IP Worked well in all apps. 
SHP-2 (Cell Signaling) WB, IP Works perfectly for WB. 
Does not IP at all. 
  
Plasmid Constructs Notes 
FAK-GFP Localizes well to focal adhesions and is 
easily detected on blots, also IP’s well 
Paxillin-GFP Localizes well to focal adhesions and is 
detected on blots. Does not IP. 
Paxillin-FLAG Used only for IP experiments. IP’s fair. 
Paxillin-dsRed Localizes well to focal adhesions. Not 
tested in other apps. 
SHP-2-EGFP (WT, D/N) Fluorescence is weak, but localizes 
normally. Can be detected by WB. 
Vinculin-GFP Localizes well to focal adhesions and is 
easily detected on blots. IP’s well. 
Talin-GFP Localizes well to focal adhesions but is not 
detected on mini-blots because protein is 
roughly 300 kDa. 
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APPENDIX F 
 
 
Laminin Activates CaMK-II to Stabilize Nascent Embryonic Axons 
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